In collaboration with the Cancer Research UK Clinical Trials Unit (CRCTU), we run an active clinical trial programme, featuring numerous NIHR Cancer Research Network-linked trials involving Birmingham-based Chief Investigators.
This involves close interaction with the CRCTU Early phase Drug Development team, and has enabled us to develop several National Cancer Research Institute-badged national trials in Birmingham.
Current clinical trials are outlined in the table below.
| Trial/Study | Therapeutic Concept | Funder | Investigator |
|---|---|---|---|
| LenaRIC | Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma | CTAAC | Dr Mark Cook |
| PICLLe | Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-Prolymphocytic Leukaemia and Mantle Cell Lymphoma. | LLR/AstraZeneca UK Ltd | Dr Guy Pratt |
| TEAMM | Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections | NIHR | Professor Mark Drayson |
| FIGARO | FIGARO - A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation | LLR | Professor Charlie Craddock |
| NCRN627 | ORAL AZACITIDINE (CC-486) IN AML OR MDS - A PHASE 1/2, DOSE AND SCHEDULE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ORAL AZACITIDINE (CC-486) IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Celgene Corporation | Professor Charlie Craddock |
| RAvVA | Phase II Randomised Trial of Azacitidine versus Azacitidine in combination with Vorinostat in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes ineligible for Intensive Chemotherapy | LLR | Professor Charlie Craddock |
| ROMAZA | ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy | LLR | Professor Charlie Craddock |
| VIOLA | A Phase I trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation | LLR | Professor Charlie Craddock |
| HA-1 Vaccine Study | HA-1 Heterologous Prime Boost Vaccine Study - A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA 'prime/boost' regimen | LLR | Professor Paul Moss |
| RICAZA | RICAZA - PHASE II STUDY OF THE TOLERABILITY OF ADJUNCTIVE AZACITIDINE IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA | Celgene International Sarl/Cure Leukaemia | Professor Charlie Craddock |
| Sodium Valproate | Sodium Valproate (Phase II study of a histone deacetylase inhibitor, sodium valproate, in AML) - Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with ATRA (all trans retinoic acid) in Patients with Acute Myeloid Leukaemia | LLR | Professor Charlie Craddock |
| CMV-ACE/ASPECT | A prospective phase II study to investigate the efficacy and safety of pre-emptive Cytomegalovirus Adoptive Cellular Therapy in patients receiving allogeneic haematopoietic stem cell transplant from an unrelated donor | LLR/Cell Medica Ltd | Dr Frederick Chen (Dr Karl Peggs National Lead; Dr F Chen PI for centralised immune monitoring and local cell manufacture) |
| CMV-IMPACT | Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study: Phase III randomised controlled study to investigate the efficacy of CMV adoptive immunotherapy given as prophylaxis | Cell Medica Ltd | (Dr Karl Peggs National Lead; Dr Frederick Chen local PI) |
| AZTEC | A single arm Phase II trial of the use of 5-Azacitidine for the treatment of patients with chronic graft-versus-host disease failing first line therapy | LLR | Dr Ram Malladi |
| CD-ON-CAT-8015-1036 | A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin | MEDIMMUNE | Local PI Frank Mussai |
| GS1101 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia | Gilead Sciences Inc. | Local PI Dr Guy Pratt |
| R-CHOP vs G-CHOP | Phase III trial of RCHOP vs G-CHOP in newly diagnosed Diffuse Large B-cell NHL | F. Hoffmann-La Roche Ltd. | Local PI Dr Guy Pratt |
| PADIMAC | Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT | LLR | Dr Kwee Yong National lead; Local PI Dr Guy Pratt |
| BaP | Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers | QEHB Charity | Professor Mark Drayson |
| R2W | R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstrom macroglobulinaemia: a randomised phase II study. | CRUK | Dr Rebecca Auer National lead; Local PI Dr Guy Pratt |
| BCD vs CCD | Phase 3 trial of Bortezomib/cyclophosphamide/dex versus Carfilzomib/cyclophosphamide/dex in relapsed multiple myeloma | Myeloma UK | Local PI Dr Guy Pratt |
| TAB-BD | Phase 2 study of tabalumab in combination with bortezomib/dexamethasone in multiple myeloma | Lilly Oncology | Local PI Dr Guy Pratt |